Back to Search

A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

  • Protocol Number: 201905035
  • Principal Investigator: Vlacich, Gregory
  • Cancer Types: Lung

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions